EP Patent

EP4599885A3 — Compounds for the treatment of glioblastoma

Assigned to Merck Patent GmbH · Expires 2025-10-15 · 1y expired

What this patent protects

The present invention encompasses cMET inhibitors for use in the treatment of glioblastoma, including disseminated glioblastoma harboring MET amplification.

USPTO Abstract

The present invention encompasses cMET inhibitors for use in the treatment of glioblastoma, including disseminated glioblastoma harboring MET amplification.

Drugs covered by this patent

tepotinib-hydrochloride (TEPOTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: EP4599885A3
Jurisdiction: EP
Classification: —
Expires: 2025-10-15
Drug substance claim: No
Drug product claim: No
Assignee: Merck Patent GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.